Core Viewpoint - The company conducted a self-examination regarding insider trading related to its 2025 restricted stock incentive plan, confirming that no insider trading occurred during the review period [1][2][3] Group 1: Self-Examination Process - The self-examination covered the period from October 25, 2024, to April 25, 2025, focusing on stock trading activities of insider information recipients [1] - The company implemented necessary confidentiality measures and registered insider information recipients as per relevant regulations [2] Group 2: Findings on Insider Trading - During the self-examination period, three insider information recipients engaged in stock trading, while others did not participate in any trading activities [2] - The trading actions of the three individuals were based on publicly disclosed information and their independent judgment, with no prior knowledge of the incentive plan [2][3] - The company found no evidence of insider trading or information leakage related to the incentive plan, confirming compliance with relevant regulations [3]

Meeting Overview - The shareholders' meeting of Nanjing Weisi Medical Technology Co., Ltd. was held on May 16, 2025, at the company's conference room in Nanjing [1] - A total of 30 ordinary shareholders attended the meeting, holding 63,795,327 voting rights, which represents 66.65% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved with a significant majority. For instance, 63,788,547 votes (99.9893%) were in favor, while only 6,780 votes (0.0107%) were against [2][3] - The voting process was conducted in accordance with the Company Law and the company's articles of association, utilizing both on-site and online voting methods [1] Legal Compliance - The meeting was presided over by the chairman, Wang Zhiyu, and all procedures followed legal requirements, ensuring the validity of the resolutions made during the meeting [3][4] - The legal opinions were provided by lawyers Qi Kaibing and Xu Rongrong, confirming that the meeting's procedures and resolutions were lawful and effective [3][4]

证券代码：688580 证券简称：伟思医疗 公告编号：2025-018 南京伟思医疗科技股份有限公司 关于公司 2025 年限制性股票激励计划 内幕信息知情人买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 4 月 24 日，南京伟思医疗科技股份有限公司（以下简称"公司"） 第四届董事会第三次会议、第四届监事会第三次会议审议通过了《关于<公司 2025 年限制性股票激励计划（草案）>及其摘要的议案》等议案，并于 2025 年 4 月 25 日在上海证券交易所网站（www.sse.com.cn）上披露了相关公告。 根据《上市公司信息披露管理办法》、公司《信息披露事务管理制度》及公 司《内幕信息知情人登记管理制度》等相关规定，公司对 2025 年限制性股票激 励计划（以下简称"本激励计划"）采取了充分必要的保密措施，同时对本激励 计划的内幕信息知情人进行了必要登记。根据《上市公司股权激励管理办法》《上 海证券交易所科创板股票上市规则》《科创板上市公司自律监管指南第 4 号—— 股权激励信 ...

证券代码：688580 证券简称：伟思医疗 公告编号：2025-019 南京伟思医疗科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 16 日 （二） 股东大会召开的地点：南京市雨花台区宁双路 19 号 H 栋公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 30 | | --- | --- | | 普通股股东人数 | 30 | | 2、出席会议的股东所持有的表决权数量 | 63,795,327 | | 普通股股东所持有表决权数量 | 63,795,327 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 66.65% | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 66.65% | 注：截至本次股东 ...

本所律师根据相关法律、法规和规范性文件的要求,按照律师行业公认的业 务标准、道德规范和勤勉尽责精神,出具法律意见如下: 法律意见书 伟思医疗 2024 年年度股东大会 江苏世纪同仁律师事务所 关于南京伟思医疗科技股份有限公司 2024 年年度股东大会的法律意见书 南京伟思医疗科技股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")《中华人民共和国 证券法》(以下简称"《证券法》")和中国证监会发布的《上市公司股东会规则》 等法律、法规和规范性文件以及《南京伟思医疗科技股份有限公司章程》(以下 简称"《公司章程》")的规定,本所受公司的委托,指派本所律师出席公司 2024 年年度股东大会,并就本次股东大会的召集、召开程序、出席会议人员资格、召 集人资格、表决程序以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东大会决议一并公告,并依法对 本法律意见书承担相应的责任。 一、关于本次股东大会的召集、召开程序 1.本次股东大会的召集 本 ...

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company is expected to experience significant growth in 2024, despite a challenging external environment and high base effects from the previous year. The launch of new products, including the MagNeuro ONE series and shockwave therapy devices, is anticipated to enhance the company's competitive edge in the rehabilitation and aesthetic medicine sectors [2][4] - The company's revenue and profit showed a notable improvement in Q1 2025, indicating a positive trend that is likely to continue throughout the year, driven by the increasing sales of aesthetic products [2] Financial Performance - In 2024, the company reported revenue of 400 million yuan, a year-over-year decrease of 13.5%, and a net profit attributable to shareholders of 101.97 million yuan, down 25.2%. The non-recurring net profit was 80 million yuan, reflecting a 31.7% decline [1][10] - For Q1 2025, the company achieved revenue of 95.91 million yuan, marking a year-over-year increase of 9.4%, and a net profit of 33.22 million yuan, up 52.7%. The non-recurring net profit was 30.54 million yuan, representing a 59.0% increase [1][10] Profitability Analysis - The gross margin for 2024 was 65.5%, a decrease of 6.3 percentage points year-over-year, while the net profit margin was 25.5%, down 4.0 percentage points. The decline in gross margin is attributed to increased competition in the rehabilitation sector and the initial phase of new product launches [3] - The operating cash flow for 2024 was 120 million yuan, a year-over-year decrease of 11.9%, with the cash flow net amount accounting for 160.1% of net operating income, showing significant improvement [3] Earnings Forecast and Valuation - The company is expected to see a gradual recovery in its core rehabilitation business and substantial contributions from new products in the aesthetic sector from 2025 to 2027. The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.37 yuan, 1.65 yuan, and 2.02 yuan, respectively. The current stock price corresponds to a price-to-earnings (P/E) ratio of 33.80 for 2025 [4][10]

Investment Rating - The investment rating for the company is "Outperform" with a target price of RMB 57.68, compared to the current price of RMB 49.90 [1]. Core Insights - The report emphasizes the company's focus on enhancing its rehabilitation core business while expanding into the emerging medical aesthetics energy source market. The company is expected to experience a second growth phase due to its strategic positioning in these sectors [1][8]. - Revenue for 2024 is projected to be RMB 400 million, a decrease of 13.45%, with a net profit attributable to shareholders of RMB 102 million, down 25.16% [8]. - The company is upgrading its core products and expanding its offerings in rehabilitation, particularly in pelvic, mental, and neurological rehabilitation [8]. Financial Summary - For 2023, the company reported revenue of RMB 462 million, with a net profit of RMB 136 million. The forecast for 2024 shows a decline in revenue to RMB 400 million and a net profit of RMB 102 million [3][5]. - The earnings per share (EPS) for 2025 and 2026 are forecasted at RMB 1.28 and RMB 1.51, respectively, with an additional forecast for 2027 at RMB 1.81 [8]. - The company maintains a net asset return rate of 6.3% for 2024, with a projected increase to 9.9% by 2027 [3][5]. Product Line Performance - The report details the performance of various product lines, indicating that electrical stimulation revenue is expected to decline by 41.75% to RMB 37 million, while magnetic stimulation revenue is projected to decrease by 13.92% to RMB 172 million in 2024 [8]. - The company is actively developing new products, including the Vishee NEO series in electrical stimulation and upgraded models in magnetic stimulation, which are set to be certified in the second half of 2024 [8]. Market Positioning - The company is strategically positioning itself in the medical aesthetics market by developing products such as shaping magnets and picosecond lasers, targeting gynecology, dermatology, and medical aesthetics applications [8]. - The report highlights the company's efforts to achieve sales breakthroughs in maternal and child channels and light medical aesthetics markets in 2024 [8].

Investment Rating - The report maintains an "Outperform" rating for the company with a target price of RMB 57.68, indicating a potential upside from the current price of RMB 49.90 [1][8]. Core Insights - The company is solidifying its rehabilitation core business while expanding into the emerging medical aesthetics energy source market. The report highlights the company's strategic upgrades in technology platforms and product lines, which are expected to drive future growth [1][8]. - Despite a weak consumption recovery, the forecasted EPS for 2025-2026 is RMB 1.28 and RMB 1.51, with an additional forecast of RMB 1.81 for 2027. The company is positioned in emerging sectors like medical aesthetics and rehabilitation robotics, suggesting potential for a second growth phase [1][8]. Financial Summary - Revenue for 2024 is projected at RMB 400 million, a decrease of 13.45% from the previous year. The net profit attributable to shareholders is expected to be RMB 102 million, down 25.16% [4][8]. - By product line for 2024: electrical stimulation revenue is RMB 37 million (-41.75%), magnetic stimulation is RMB 172 million (-13.92%), electrophysiology is RMB 65 million (+0.25%), consumables and accessories are RMB 79 million (+4.14%), and laser radiofrequency is RMB 30 million (-20.87%) [4][8]. - The company is focusing on core product upgrades and expansion in rehabilitation, with significant developments in electrical stimulation and magnetic stimulation products expected to be certified in 2024 [4][8]. Emerging Market Strategy - The company is increasing investments in emerging fields, particularly in the medical aesthetics energy source market. It has developed products such as shaping magnets, picosecond lasers, and radiofrequency devices, targeting gynecology, dermatology, and medical aesthetics [4][8]. - Sales breakthroughs are anticipated in maternal and child channels and light medical aesthetics markets for 2024, with the Nd:YAG frequency-doubled picosecond laser already certified [4][8].

Core Points - The company board received a resignation application from Vice President Zhong Yiqun due to reaching the legal retirement age [1] - After retirement procedures are completed, Zhong will continue to work as a management consultant for the "Weisi Medical Headquarters R&D Economic Park Project" [1] - Zhong holds 34,125 shares, representing 0.04% of the company's total share capital, and will comply with relevant regulations regarding share management post-resignation [1][2] Summary of Related Sections - Zhong Yiqun has adhered to laws and company regulations during her tenure, and the board expresses gratitude for her contributions to the company's development [2] - The resignation will not impact the company's operations [1]

南京伟思医疗科技股份有限公司 关于高级管理人员退休辞任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京伟思医疗科技股份有限公司（以下简称"公司"）董事会于近日收到公 司副总经理钟益群女士提交的申请，因已到法定退休年龄,申请辞去公司副总经 理的职务。钟益群女士退休手续办理完毕后，公司将以退休返聘的形式继续聘用 钟益群女士担任公司"伟思医疗总部研发经济园项目"建设等工作的管理顾问， 除此之外，将不再担任公司或子公司任何其他职务。根据法律法规、规范性文件 及《中华人民共和国公司法》等有关规定，钟益群女士的辞职报告自送达公司董 事会之日起生效，其辞任不会对公司的生产经营产生影响。 截至本公告日，钟益群女士直接持有公司股份 34,125 股，占公司总股本的 则》《上海证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施 细则》等相关法律法规，管理其所持有股份，严格履行做出的各项承诺。 钟益群女士在担任公司副总经理期间，严格遵守法律法规及《公司章程》 的有关规定，忠实履行作出的声明及承诺，恪尽职守，勤勉尽责，公司及 ...